2023 World Conference on Lung Cancer (Posters)-EP12.01. Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer

EP12.01. Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the clinical features, outcomes, and biology of EGFR exon 20 insertions (exon20ins) in a cohort of Hispanic patients with non-small cell lung cancer (NSCLC). The study reviewed clinical records of patients from multiple cancer centers in Latin America and the United States. A total of 93 patients with EGFR exon20ins mutation advanced NSCLC were included in the analysis.<br /><br />The results showed that the most common EGFR exon20ins subtypes were H773insH, V769_D770insASV, H773_V774insPH, and A763_Y764insFQEA. The treatments received by the patients included chemotherapy (52.7%), 1st-generation tyrosine-kinase inhibitors (TKIs) (21.5%), CTBevacizumab (11.8%), CTpembrolizumab (4.3%), osimertinib (3.2%), afatinib (3.2%), and other regimens (3.2%).<br /><br />The study found that CTBevacizumab and TKIs had longer median progression-free survival (mPFS) compared to chemotherapy alone in the first-line treatment. Osimertinib and afatinib did not improve mPFS significantly. In terms of median overall survival (mOS), osimertinib, CTBevacizumab, and first-generation TKIs had longer mOS compared to chemotherapy alone. However, CTpembrolizumab and afatinib did not improve mOS.<br /><br />Six patients who were treated with anti-EGFR exon20ins agents (amivantamab and mobocertinib) during different lines of treatment had a longer mOS compared to those who did not receive an exon20ins-directed agent, although without statistical significance.<br /><br />The study concluded that osimertinib, CTBevacizumab, and 1st-generation TKIs discreetly improved mPFS and mOS compared to chemotherapy in Hispanic patients with EGFR exon20ins NSCLC. The authors also suggested that anti-EGFR exon20ins agents might be a better option to improve overall survival in this population, highlighting the need for better treatment options for NSCLC patients in Latin America.

Asset Subtitle

Andres Cardona

Meta Tag

Speaker Andres Cardona

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

EGFR exon20ins

NSCLC

Hispanic patients

chemotherapy

TKIs

CTBevacizumab

osimertinib

afatinib

mPFS

mOS